Company Filing History:
Years Active: 2018-2022
Title: Laura Carter: Innovating in Immunotherapy
Introduction
Laura Carter, an accomplished inventor based in Ann Arbor, MI, has made significant contributions to the field of immunotherapy. With a total of three patents to her name, Carter's work focuses on developing innovative solutions that target specific immune responses, particularly through the modulation of interleukin-21 (IL-21).
Latest Patents
Carter's latest patents revolve around "Antibodies specific for IL-21 and uses thereof." This groundbreaking disclosure introduces IL-21 binding molecules, including anti-IL-21 antibodies and their antigen-binding fragments. These molecules are designed to inhibit, suppress, or antagonize IL-21 activity, which is crucial for managing various inflammatory and autoimmune diseases. Her research outlines methods for diagnosing and treating conditions linked to IL-21-mediated signal transduction and presents innovative approaches to prevent Graft-versus-host disease (GVHD) through the application of these antibodies.
Career Highlights
Currently, Laura Carter is affiliated with Boston Pharmaceuticals, Inc., where her expertise in antibody development is utilized to advance therapeutic options for patients with immune-mediated disorders. Her innovative approach and dedication to research have positioned her as an influential figure in the pharmaceutical industry, particularly in the realm of immunotherapy.
Collaborations
Throughout her career, Carter has collaborated with several notable individuals, including her coworkers Catherine Ettinger and Jodi Karnell. These partnerships have enhanced the scope and impact of her research, fostering a collaborative environment that encourages the sharing of knowledge and expertise.
Conclusion
Laura Carter exemplifies the spirit of innovation within the field of immunology. Her contributions through patentable inventions not only advance scientific understanding but also have the potential to significantly improve treatment outcomes for patients suffering from autoimmune diseases. Her ongoing work continues to inspire future research and development in the area of targeted therapeutics.